Skip to main content
. 2020 May 1;10(5):1548–1567.

Table 2.

The relationship between SCL25A18 expression and clinicopathological characteristics of CRC cases from the TCGA database

Clinic pathological characteristics Expression level of SLC25A18 mRNA Number of cases P-value

High (%) Low (%)
Gender
    Male 213 (34.4) 116 (18.7) 619 0.4369
    Female 179 (28.9) 111 (17.9)
Primary Site
    Colon 290 (47.2) 163 (26.5) 615 0.5102
    Rectal 99 (16.1) 63 (10.2)
Histological type
    Colon Adenocarcinoma 248 (40.8) 139 (22.9) 608 0.4629
    Colon Mucinous Adenocarcinoma 41 (6.7) 21 (3.5)
    Rectal Adenocarcinoma 86 (14.1) 60 (9.9)
    Rectal Mucinous Adenocarcinoma 10 (1.6) 3 (0.5)
Ethnicity
    White 130 (35.1) 162 (43.8) 370 0.8831
    Non-White 34 (9.2) 44 (11.9)
Pathologic T stage
    T1 and T2 96 (15.5) 29 (4.7) 618 0.0004****
    T3 and T4 295 (47.7) 198 (32)
Pathologic N stage
    N0 234 (37.9) 117 (18.9) 617 0.0401**
    N1 and N2 156 (25.2) 110 (17.8)
Pathologic M stage
    M0 301 (55.0) 158 (28.9) 547 0.8844
    M1 57 (10.4) 31 (5.7)
Microsatellite instability
    MSI 5 (4.3) 6 (5.2) 116 0.9869
    MSS 48 (41.4) 57 (49.1)
Residual tumor
    R0 307 (62.3) 144 (29.2) 493 0.1595
    R1 and R2 33 (6.7) 9 (1.8)
Survival status
    Alive 355 (57.4) 199 (32.2) 618 0.3243
    Dead 37 (6.0) 27 (4.4)
Vascular invasion
    Yes 82 (15.3) 50 (9.3) 537 0.7824
    No 257 (47.9) 148 (27.6)
Lymphatic invasion
    Yes 160 (28.7) 68 (12.2) 558 0.0113**
    No 197 (35.3) 133 (23.8)
Perineural invasion
    Yes 23 (10.0) 37 (16.0) 231 0.4105
    No 76 (32.9) 95 (41.1)
Tumor deposits
    Yes 24 (8.2) 25 (8.5) 293 0.8540
    No 116 (39.6) 128 (43.7)
KRAS Mutation
    Yes 13 (21.0) 18 (29.0) 62 0.6020
    No 11 (17.7) 20 (32.3)
BRAF Mutation
    Yes 1 (2.9) 2 (5.7) 35 0.5460
    No 6 (17.1) 26 (74.3)
Mismatch repair protein present
    Yes 36 (7.6) 28 (5.9) 471 0.0072***
    No 296 (62.8) 111 (23.6)

Clinical data were investigated using chi-square test.

**

P < 0.05;

***

P < 0.01;

****

P < 0.001.